GL Biochem (Shanghai): difference between revisions
Diff·revision 23 → 24·13:02, 10 May 2025
Difference between revision 23 and revision 24 of GL Biochem (Shanghai). 9 lines changed; the page grew by 539 bytes.
| Revision 23 — 04:21, 17 Apr 2025 PurityClaimPia (talk) clarify that no manufacturing or marketing authorisation is claimed or established 13,777 bytes +810 | Revision 24 — 13:02, 10 May 2025 CiteBot (talk) bot: normalise citation format 14,316 bytes +539 | ||
|---|---|---|---|
| 77 | Material described here is labelled [[Research use only|for research use only]] and is '''not approved for human use''' in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them. | 77 | Material described here is labelled [[Research use only|for research use only]] and is '''not approved for human use''' in any jurisdiction. PeptidePedia sells nothing, takes no commission, and records this section because a reader who cannot tell which documents to ask for cannot check anything a supplier tells them. |
| 78 | 78 | ||
| + | 79 | [https://glbiochem.net/ Go to the GL Biochem catalogue →] | |
| + | 80 | ||
| 79 | == Reception == | 81 | == Reception == |
| 80 | The PeptidePedia tally records 1,962 self-reported submissions to July 2026, the largest count in this group and consistent with a longer history and a wider customer base. Recurring themes are documentation completeness and the synthesis of difficult sequences — hydrophobic runs, long sequences and cyclisations that submissions describe as having been declined elsewhere.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} | 82 | The PeptidePedia tally records 1,962 self-reported submissions to July 2026, the largest count in this group and consistent with a longer history and a wider customer base. Recurring themes are documentation completeness and the synthesis of difficult sequences — hydrophobic runs, long sequences and cyclisations that submissions describe as having been declined elsewhere.{{r|tally}} Self-selected; reception rather than quality.{{r|tally}} |
| ⋮ | ⋮ | ||
| 89 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} | 91 | * '''It is not comparable across communities.''' Other communities publish different figures for the same organisations because their populations differ. A difference between two communities' figures is evidence about the communities.{{r|tally}} |
| 90 | 92 | ||
| + | 93 | PeptidePedia does not rank suppliers and does not maintain a league table. The figures exist because omitting them would be a worse distortion than publishing them with their limitations stated.{{r|tally}} | |
| + | 94 | ||
| 91 | == Regulatory position and legal status == | 95 | == Regulatory position and legal status == |
| 92 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} | 96 | The organisation is a commercial entity registered in the People's Republic of China. Nothing in the available record indicates a manufacturing authorisation, marketing authorisation or pharmacopoeial registration in any jurisdiction, and none should be inferred from a registered business scope, which is a licensing fact and not a quality assurance.{{r|registry}} |
| ⋮ | ⋮ | ||
| 105 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> | 109 | <ref name="gmp">World Health Organization, ''Good Manufacturing Practices for Pharmaceutical Products: Main Principles'', WHO Technical Report Series. The general framework against which a GMP claim is assessed.</ref> |
| 106 | 110 | ||
| + | 111 | == Further reading == | |
| + | 112 | * [[Project:Vendor notability]] — the criteria under which this article exists, and what supplier articles may not contain. | |
| + | 113 | * [[Project:Sourcing guidelines]] — how test reports and community tallies are cited on this wiki. | |
| + | 114 | ||
| 107 | == See also == | 115 | == See also == |
| 108 | * [[Certificate of analysis]] | 116 | * [[Certificate of analysis]] |
| ⋮ | ⋮ | ||
| 112 | * [[Research use only]] | 120 | * [[Research use only]] |
| 113 | * [[Peptide supply chain]] | 121 | * [[Peptide supply chain]] |
| + | 122 | * [[Blind sampling]] | |
| 114 | 123 | ||
| 115 | {{DEFAULTSORT:GL Biochem (Shanghai)}} | 124 | {{DEFAULTSORT:GL Biochem (Shanghai)}} |